For patients in the AD remission group, compared with the values before treatment, posttreatment serum levels of IL-4 and IL-13 reduced significantly (all P < 0.05), IFN and IL-12 levels increased significantly (all P < 0.05), and IL-10 and TGF-β levels remained unchanged (Figure 5). The gene discussed is IL13; the disease is Alzheimer disease.